The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma

GSK256066 is a selective phosphodiesterase 4 inhibitor that can be given by inhalation, minimising the potential for side effects. We evaluated the effects of GSK256066 on airway responses to allergen challenge in mild asthmatics. METHODS: In a randomised, double blind, cross-over study, 24 steroid...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Dave, Petavy, Frank, Macdonald, Alex J, Lazaar, Aili L, O'Connor, Brian J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2841147/
https://www.ncbi.nlm.nih.gov/pubmed/20193079
http://dx.doi.org/10.1186/1465-9921-11-26

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2841147/
https://www.ncbi.nlm.nih.gov/pubmed/20193079
http://dx.doi.org/10.1186/1465-9921-11-26

Ejemplares similares